P reexposure prophylaxis (PrEP) involves use of antiretroviral therapy regularly (eg, daily) or before and after possible HIV exposure events such as sex ("on-demand" or "event-driven") to decrease risk of acquiring HIV infection. The purpose of this report was to synthesize the evidence on effects of PrEP on HIV acquisition risk,mortality,harms,andotherclinicaloutcomes;effectsofadherence on PrEP-associated outcomes; and accuracy of methods for identifying potential candidates for PrEP. It was used by the United States Preventive Services Task Force (USPSTF) to develop a new recommendation on PrEP for the prevention of HIV infection.
Methods

Scope of the Review
Detailed methods are available in the full evidence report at https:// www.uspreventiveservicestaskforce.org/Page/Document/ UpdateSummaryFinal/prevention-of-human-immunodeficiencyvirus-hiv-infection-pre-exposure-prophylaxis. Figure 1 shows the analytic framework and key questions (KQs) that guided the review. The full report also includes contextual questions (not systematically reviewed) that addressed factors associated with PrEP adherence and rates of antiretroviral drug-resistant HIV in PrEP-treated individuals.
Data Sources and Searches
Ovid MEDLINE, the Cochrane Library, and EMBASE were searched for English-language articles published from inception through June 2018 (eMethods 1 in the Supplement). Searches were supplemented by review of reference lists of included studies. Since June 2018, ongoing surveillance was conducted through article alerts and targeted searches of journals to identify major studies published in the interim that may affect the conclusions or understanding of the evidence and the related USPSTF recommendation. The last surveillance was conducted on January 25, 2019, and identified no eligible randomized trials.
Study Selection
Two investigators independently reviewed titles, abstracts, and full-text articles using predefined eligibility criteria. Randomized clinical trials (RCTs) of PrEP vs placebo or no PrEP in HIVuninfected adults and adolescents (13-18 years) at higher risk for acquiring HIV were eligible for KQ1 and KQ5. Trials had to evaluate oral combination tenofovir disoproxil fumarate/emtricitabine or tenofovir disoproxil fumarate monotherapy and report HIV infection, mortality, quality of life, or harms. Tenofovir disoproxil fumarate/emtricitabine is the only medication approved by the US Food and Drug Administration (FDA) and recommended for PrEP; tenofovir disoproxil fumarate monotherapy is an alternate regimen for people who inject drugs (PWID) and in persons at risk because of heterosexual behavior. 2 Studies of the diagnostic accuracy of instruments to predict HIV acquisition in the United States or US-applicable settings were eligible for KQ2. United States-based RCTs and observational studies of PrEP implementation that reported adherence were eligible for KQ3 and KQ4. 3, 4 Data Abstraction and Quality Rating
For each included study, 1 investigator abstracted information on populations, interventions or screening instruments, comparators, adherence, outcomes, study designs, and settings. A second investigator reviewed abstracted information for accuracy. Two independent investigators assessed the quality of each study as good, fair, or poor using predefined criteria developed by the USPSTF (eMethods 2 in the Supplement). Quality ratings for individual studies are provided in eTables 1-3 in the Supplement. For all KQs, the overall strength of the body of evidence was assessed as high, moderate, low, or insufficient using methods developed for the USPSTF, based on the overall quality of studies, consistency of results between studies, precision of findings, and risk of reporting bias. 1 The applicability of the findings to US primary care populations and settings was also assessed.
Data Synthesis
Meta-analysis was conducted to calculate pooled relative risks (RRs) for effects of PrEP vs placebo or no PrEP on HIV infection, mortality, and harms, using the DerSimonian and Laird randomeffects model in Review Manager Version 5.3 (Cochrane Collaboration Nordic Cochrane Centre). Statistical heterogeneity was assessed using the I 2 statistic. 5 When I 2 was greater than 30%, the analysis was also performed with the profile likelihood method using Stata/IC Version 13.1 (StataCorp). 6 Results using the profile likelihood method were similar to those from the DerSimonian and Laird model and are not reported in this article. Sensitivity analyses and stratified analyses were conducted on study quality, PrEP regimen, HIV risk category, dosing schedule, study duration, and country. Stratified analyses were assessed for interactions using a test for heterogeneity across subgroups. Sensitivity analyses were also conducted using data from the FDA medical review of PrEP 7 on HIV incidence and fracture rates in place of data reported in journal articles when there were discrepancies. Results were very similar, and this article presents findings based on journal article data. Study-level adherence was assessed as a categorical variable in a stratified analysis (Ն70%, >40% to <70%, or Յ40%) 8 and as a continuous variable through meta-regression, and a plot of adherence against effectiveness (log RR) was constructed. For trials that used multiple adherence measurement methods, adherence data were selected using a prioritized list. 9 For analyses with at least 10 trials, funnel plots were constructed and the Egger test conducted for small sample effects.
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All significance testing was 2-tailed; P values of .05 or less were considered statistically significant.
Results
Across all KQs, 14 RCTs (in 37 articles ) (N = 18 837), 8 observational studies [48] [49] [50] [51] [52] [53] [54] [55] (N = 3884), and 7 studies of diagnostic accuracy of HIV risk prediction instruments [56] [57] [58] [59] [60] [61] [62] (N = 32 279) were included ( Figure 2) . The main results for each key question are summarized below. A stratified analysis found a significant interaction (P < .001) between level of adherence (Յ40%, >40 to <70%, or Ն70%) and effectiveness of PrEP; stratification by adherence eliminated statistical heterogeneity (Table 2, Figure 4 ). In 6 trials (n = 7328) with adherence 70% or greater, the RR was 0.27 (95% CI, 0.19-0.39; I 2 = 0%).
Benefits of PrEP
12,18,31,33,39,42 There was also a strong association between effectiveness and adherence analyzed as a continuous variable (P < .001) (eFigure 2 in the Supplement), which accounted for all of the between-study heterogeneity. Findings were similar when analyses were restricted to trials that evaluated adherence based on plasma levels. PrEP was effective across HIV risk categories (persons at risk because of heterosexual contact, men who have sex with men, or PWID; P = .43 for interaction) ( Estimates were similar when trials were stratified according to duration of follow-up, when the analysis was restricted to good-quality trials, or when trials were stratified according to whether they reported some industry support (usually donated study drugs) ( Table 2 ). The estimate from 1 trial (n = 400) of event-driven PrEP (RR, 0.14 [95% CI, 0.03-0.63]) was similar to the pooled estimate from daily-dosing trials that reported high adherence (5 For men who have sex with men, studies evaluated the predictive utility of 4 different instruments (number of criteria ranged from 4 to 10). For 3 instruments (n = 20 064), discrimination was similar, with area under the receiver operating characteristic (AUROC) curves in the original validation cohorts ranging from 0.66 to 0.72. found that all participants with seroconversion receiving PrEP had undetectable plasma levels of tenofovir or levels consistent with low adherence. The number of participants with seroconversion in each study was small (1 to 4 patients per study).
Harms of PrEP
Key Question 5. What are the harms of PrEP vs placebo or no PrEP when used for the prevention of HIV infection? There were no significant differences between PrEP vs placebo or no PrEP in risk of gonorrhea, chlamydia, or syphilis (Table 3) (n = 2120) found no significant difference in risk of any adverse pregnancy outcome. 34 For all adverse events, there was no statistically significant interaction between PrEP regimen and any adverse event except for gonorrhea and chlamydia infection (Table 3) . However, for both of these adverse events there was only 1 trial of tenofovir disoproxil fumarate. There was no statistically significant interaction between HIV risk category and risk of STIs.
Discussion
The findings in this evidence report are summarized in Table 4 . In populations at increased HIV infection risk, PrEP was associated with decreased risk of acquiring HIV infection that varies according to the level of adherence. In trials for which adherence was 70% or greater, the reduction in risk was approximately 75%, with a number needed to treat of approximately 33. 12 Data on effects on PrEP in pregnancy were very limited. Trials excluded pregnant women and discontinued PrEP at the time pregnancy was confirmed. FDA labeling information and perinatal antiretroviral treatment guidelines permit use of tenofovir disoproxil fumarate/emtricitabine during pregnancy, although guidelines note that data on safety of PrEP during pregnancy and lactation are limited. 73 For predicting incident HIV infection, several instruments in men who have sex with men 56-59 and 1 instrument in PWID 60 were associated with moderate discrimination, but studies had methodological shortcomings. Discrimination was poorer in some studies of black men who have sex with men, 61,62 and all instruments require further validation. Instruments for predicting risk of HIV infection in women were developed using African cohorts.
Research is needed to directly compare effects of daily vs alternative PrEP dosing strategies in studies adequately powered to assess effects on HIV infection 45, 46 ; to verify the effectiveness of PrEP in high-income settings in persons at higher risk because of heterosexual contact and PWID; to determine the safety and effectiveness of PrEP during pregnancy or lactation and in transgender women and men; to understand effectiveness and long-term safety in adolescents; to understand effects of PrEP on quality of life; to understand effects of PrEP on behavioral risk compensation using open-label studies; to develop accurate instruments for identifying persons at higher risk for acquiring HIV infection; and to determine methods for increasing uptake and adherence to PrEP, to optimize effectiveness. Research on a number of alternative PrEP drugs and regimens is ongoing. Clinical 
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Limitations
This review had some limitations. First, the DerSimonian and Laird random-effects model was used to pool studies, which may result in CIs that are too narrow, particularly when heterogeneity is present. 6 However, analyses were repeated using the profile likelihood method, which resulted in similar findings. Second, these findings are based on analyses of study-level data, limiting the ability to evaluate subgroup effects. Third, non-English-language articles were excluded, but large non-English-language trials of PrEP were not identified. Fourth, in the pooled analysis of HIV infection, graphical and statistical tests indicated small sample effects, a potential marker for publication bias. However, no unpublished PrEP trials were identified in searches on a clinical trials registry (ClinicalTrials.gov) or reviews of reference lists. Fifth, trials of PrEP in persons at risk because of heterosexual contact were conducted in Africa and 1 trial of PrEP in PWID was conducted in Asia, which could limit applicability to the United States and other high-income settings.
Conclusions
In adults at increased risk of HIV infection, PrEP with oral tenofovir disoproxil fumarate monotherapy or tenofovir disoproxil fumarate/ emtricitabine was associated with decreased risk of HIV infection compared with placebo or no PrEP, although effectiveness decreased with suboptimal adherence. 
